Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bullfrog AI Holdings, Inc. Common Stock (BFRG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BFRG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $
1 Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -83.98% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.22M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.64 | 52 Weeks Range 1.23 - 4.84 | Updated Date 06/29/2025 |
52 Weeks Range 1.23 - 4.84 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -78.05% | Return on Equity (TTM) -141.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10607832 | Price to Sales(TTM) 262.62 |
Enterprise Value 10607832 | Price to Sales(TTM) 262.62 | ||
Enterprise Value to Revenue 205.12 | Enterprise Value to EBITDA -12.02 | Shares Outstanding 9415520 | Shares Floating 7018332 |
Shares Outstanding 9415520 | Shares Floating 7018332 | ||
Percent Insiders 25.96 | Percent Institutions 4.5 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bullfrog AI Holdings, Inc. Common Stock
Company Overview
History and Background
Bullfrog AI Holdings, Inc. focuses on developing and commercializing analytics solutions for complex diseases. Founded relatively recently, it aims to revolutionize drug development through its proprietary bfLEAPu2122 platform.
Core Business Areas
- Drug Development Analytics: Provides predictive analytics to accelerate drug discovery and development, improve clinical trial outcomes, and enable precision medicine.
- Defense Applications: Applies its analytics platform to defense and national security challenges, such as threat assessment and countermeasure development.
- Government Applications: Provides data-driven insights for various government sectors.
Leadership and Structure
Leadership details are available on their website but are not included here due to the evolving nature and access constraints. The company has a board of directors and a management team overseeing operations.
Top Products and Market Share
Key Offerings
- bfLEAPu2122 Platform: A proprietary analytics platform that uses machine learning to identify patterns and predict outcomes in complex data sets. It finds patterns in highly dimensional data and allows users to predict outcomes. Market share data unavailable, key competitors includes BioSymetrics and GNS Healthcare. Precise revenue from this product is not publicly available.
Market Dynamics
Industry Overview
The healthcare analytics market is experiencing rapid growth, driven by the increasing availability of data, the need to improve drug development efficiency, and the growing adoption of precision medicine. This growth trend is also evident in other markets, such as defense, finance, and cybersecurity.
Positioning
Bullfrog AI aims to be a leader in predictive analytics for complex diseases, leveraging its unique bfLEAPu2122 platform. Competitive advantages are claimed in handling high-dimensional data and providing actionable insights. There is strong competition, but Bullfrog AI differentiates itself with its proprietary technology.
Total Addressable Market (TAM)
The total addressable market for AI in drug discovery is substantial, estimated to be in the billions of dollars. Bullfrog AI is positioned to capture a share of this market by providing analytics solutions that accelerate drug development and improve clinical trial outcomes.
Upturn SWOT Analysis
Strengths
- Proprietary bfLEAPu2122 platform
- Focus on complex diseases
- Potential for disruptive innovation
- Experience with defense & government applications
Weaknesses
- Limited financial resources
- Dependence on successful commercialization of bfLEAPu2122
- Small market share
- Lack of robust scientific backing
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Increased adoption of AI in drug development
- Government funding for AI-driven research
Threats
- Competition from larger, established players
- Regulatory hurdles in drug development
- Rapid advancements in AI technology rendering bfLEAPu2122 obsolete
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- GNS Healthcare (Privately Held)
- BioSymetrics (Privately Held)
- Recursion Pharmaceuticals, Inc. (RXRX)
Competitive Landscape
Bullfrog AI faces intense competition from larger companies with more established platforms and resources. Its competitive advantage lies in the bfLEAPu2122 platform and its focus on complex diseases. Its small size, however, limits its impact relative to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable given the company's recent entry into the public market.
Future Projections: Future growth projections are dependent on successful commercialization of the bfLEAPu2122 platform and partnerships with pharmaceutical companies. Analyst estimates are limited due to the company's early stage.
Recent Initiatives: Recent initiatives include seeking partnerships with pharmaceutical companies and expanding its applications of the bfLEAPu2122 platform.
Summary
Bullfrog AI is a developing company that is looking to revolutionize drug development using its bfLEAPu2122 platform for complex diseases and its experience in the defense and government sectors. Limited resources and small market share create some problems in realizing this ambition, especially against bigger players in the field. Partnerships and further adoption of its product are key to long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Third-party Market Research
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The information is current as of October 27, 2024, and may be subject to change. Market share estimates are approximations. Due to the rapidly changing nature of the market and data constraints, the accuracy of this analysis is limited. Financial performance should be independently verified.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bullfrog AI Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2023-02-13 | Founder, Chairman & CEO Mr. Vininder Singh | ||
Sector Healthcare | Industry Health Information Services | Full time employees - | Website https://www.bullfrogai.com |
Full time employees - | Website https://www.bullfrogai.com | ||
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It also has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.